MedTrace Logo

CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)

NCT00219973 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 526

Last updated 2010-04-28

No results posted yet for this study

Summary

The aim of the study is to evaluate the efficacy and safety of Bemiparin, a second-generation LMWH, in the prophylaxis of VTE (using a postoperative regimen, i.e. administering the first dose 6 hours after finishing the surgical procedure) for 28 days compared to 8 days, in oncological surgery.

Conditions

  • Cancer
  • Venous Thromboembolism

Interventions

DRUG

Bemiparin

Bemiparin 3.500 IU/day for 28 days compared to 8 days

Sponsors & Collaborators

  • Rovi Pharmaceuticals Laboratories

    lead INDUSTRY

Principal Investigators

  • Vijay V Kakkar, Prof. · Thrombosis Research Institute (London, UK)

  • Paolo Prandoni, Prof. · Faculty of Medicine, University of Padova (Padova, Italy)

  • Jose Luis Balibrea-Cantero, Prof. · Faculty of Medicine, Complutense University (Madrid, Spain)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Completion
2009-04-30

Countries

  • Portugal
  • Romania
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219973 on ClinicalTrials.gov